Roche and AbbVie’s Venclexta approved in CLL
Deal is based on natural killer cell therapeutics
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.
Pharmaceutical Microbiology West Coast Conference 2018
Data suggest high dose used in phase 3 trial is most effective